Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies
Journal of Alzheimer’s Disease · 2023
DOI: 10.3233/jad-230127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2023. Verfasst von Geri Meduri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institut Professeur Baulieu, Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: Tauopathies, Alzheimer Disease, Frontotemporal Lobar Degeneration. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Pathological tau proteins constitute neurofibrillary tangles that accumulate in tauopathies including Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), and familial frontotemporal lobar degeneration (FTLD-Tau). We previously showed that the FKBP52 immunophilin interacts functionally with tau and strongly decreases in AD brain neurons in correlation with tau deposition. We also reported that FKBP52 co-localizes with autophagy-lysosomal markers and an early pathological tau isoform in AD neurons, suggesting its involvement in autophagic tau clearance.
Objective
Our objective was to evaluate if differences in neuronal FKBP52 expression levels and subcellular localization might be detected in AD, PSP, familial FTLD-Tau, and in the hTau-P301 S mouse model compared to controls.
Methods
Cell by cell immunohistofluorescence analyses and quantification of FKBP52 were performed on postmortem brain samples of some human tauopathies and on hTau-P301 S mice spinal cords.
Results
We describe a similar FKBP52 decrease and its localization with early pathological tau forms in the neuronal autophagy-lysosomal pathway in various tauopathies and hTau-P301 S mice. We find that FKBP52 decreases early during the pathologic process as it occurs in rare neurons with tau deposits in the marginally affected frontal cortex region of AD Braak IV brains and in the spinal cord of symptomless 1-month-old hTau-P301 S mice.
Conclusion
As FKBP52 plays a significant role in cellular signaling and conceivably in tau clearance, our data support the idea that the prevention of FKBP52 decrease or the restoration of its normal expression at early pathologic stages might represent a new potential therapeutic approach in tauopathies including AD, familial FTLD-Tau, and PSP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Professeur Baulieu, Kremlin-Bicêtre, France.
- Department of Biosciences, Biotechnology and Biopharmacology, UNIBA University, Bari, Italy.
- Université Paris-Saclay, INSERM U1195, Kremlin-Bicêtre, France.
Zitieren
APA
Meduri, G., Guillemeau, K., Daguinot, C., Dounane, O., Genet, M., Ferrara, L., Chambraud, B., Baulieu, E. E., & Giustiniani, J. (2023). Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-230127
Vancouver
Meduri G, Guillemeau K, Daguinot C, Dounane O, Genet M, Ferrara L, et al. Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies. Journal of Alzheimer’s Disease. 2023. doi:10.3233/jad-230127
BibTeX
@article{Meduri2023,
author = {Meduri, Geri and Guillemeau, Kevin and Daguinot, Corentin and Dounane, Omar and Genet, Melanie and Ferrara, Luigi and Chambraud, Beatrice and Baulieu, Etienne Emile and Giustiniani, Julien},
title = {Concomitant Neuronal Tau Deposition and FKBP52 Decrease Is an Early Feature of Different Human and Experimental Tauopathies},
journal = {Journal of Alzheimer’s Disease},
year = {2023},
doi = {10.3233/jad-230127}
}
EUVIMED